- $945.25m
- $1.20bn
- $310.46m
- 87
- 85
- 87
- 98
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.35 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -48.91% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.4 | ||
| Price to Tang. Book | 2.76 | ||
| Price to Free Cashflow | 6.72 | ||
| Price to Sales | 3.04 | ||
| EV to EBITDA | 8.01 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.45% | ||
| Return on Equity | 28.97% | ||
| Operating Margin | 36.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 261.02 | 336.79 | 391.87 | 331.34 | 310.46 | 300.74 | 333.75 | 3.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -60.19 | +45.48 | +42.2 | -89.94 | +616.74 | -60.86 | +20.99 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).
Directors
- Odysseas Kostas CHM (46)
- Pavel Raifeld CEO (37)
- Marianne Zhen CAO (52)
- George Bickerstaff IND (65)
- Deborah Birx IND (64)
- Mark Dipaolo IND (50)
- Jules Haimovitz IND (70)
- Sarah Schlesinger IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 19th, 1996
- Public Since
- October 5th, 2004
- No. of Shareholders
- 63
- No. of Employees
- 112
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 63,227,333
- Address
- 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME, 94010
- Web
- https://www.inva.com/
- Phone
- +1 6502389600
- Auditors
- Deloitte & Touche LLP
Upcoming Events for INVA
Q2 2024 Innoviva Inc Earnings Release
Similar to INVA
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the Innoviva share price?
As of Today at 19:11 UTC, shares in Innoviva are trading at $14.95. This share price information is delayed by 15 minutes.
How has the Innoviva share price performed this year?
Shares in Innoviva last closed at $14.95 and the price had moved by +26.27% over the past 365 days. In terms of relative price strength the Innoviva share price has outperformed the S&P500 Index by +5.07% over the past year.
What are the analyst and broker recommendations for Innoviva?
The overall consensus recommendation for Innoviva is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Innoviva dividend yield?
Innoviva does not currently pay a dividend.
Does Innoviva pay a dividend?
Innoviva does not currently pay a dividend.
When does Innoviva next pay dividends?
Innoviva does not currently pay a dividend.
How do I buy Innoviva shares?
To buy shares in Innoviva you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Innoviva?
As of the previous close price of $14.95, shares in Innoviva had a market capitalisation of $945.25m.
Where are Innoviva shares listed?
Here are the trading details for Innoviva:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: INVA
What kind of share is Innoviva?
Based on an overall assessment of its quality, value and momentum Innoviva is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Innoviva share price forecast for 2024?
The analyst consensus target price for shares in Innoviva is $15.00. That is 0.33% above the last closing price of $14.95.
Analysts covering Innoviva currently have a consensus Earnings Per Share (EPS) forecast of $0.81 for the next financial year.
What is the trend in the Innoviva share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Innoviva. Over the past six months, its share price has underperformed the S&P500 Index by -1.15%.
As of the last closing price of $14.95, shares in Innoviva were trading +4.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Innoviva PE Ratio?
The Innoviva PE ratio based on its reported earnings over the past 12 months is 17.35. The shares last closed at $14.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Innoviva?
Innoviva's management team is headed by:
- Odysseas Kostas - CHM
- Pavel Raifeld - CEO
- Marianne Zhen - CAO
- George Bickerstaff - IND
- Deborah Birx - IND
- Mark Dipaolo - IND
- Jules Haimovitz - IND
- Sarah Schlesinger - IND